Synthetic Strategy and Evaluation of the Benzyloxy Benzylamide Derivatives as Thymic Stromal Lymphopoietin Modulators for the Treatment of Atopic Dermatitis
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.5c02461 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Kyoung Hee Seo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Cytokines, Amides. Die Arbeit nennt 51 Literaturangaben. Gefördert von: Korea Drug Development Fund, National Research Foundation of Korea.
Abstract (Originalsprache)
Atopic dermatitis (AD) is a chronic inflammatory skin disease driven by immune dysregulation, in which thymic stromal lymphopoietin (TSLP) plays a critical role by triggering type 2 inflammation and exacerbating disease progression. In this study, a screening of our in-house library for inhibition of CCL17 mRNA expression led to identification of hit compound 6a. Based on this scaffold, benzyloxy benzylamide derivatives were systematically designed and synthesized, followed by the evaluation of their anti-inflammatory potential. Among them, compound 14o exhibited the most potent inhibition of CCL17 and IL-1B mRNA expression in HaCaT keratinocytes, along with favorable drug-like properties. 14o interfered with TSLP receptor dimerization and suppressed the TSLP-induced signal transducer and activator of transcription 5 phosphorylation. Furthermore, 14o significantly attenuated TSLP-induced calcium influx and effectively alleviated pruritus and AD-like symptoms in a house dust mite (HDM)-induced AD mouse model. Collectively, these findings highlight 14o as a promising topical therapeutic candidate targeting TSLP signaling for the treatment of AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea.
- Division of Bio-Medical Science & Technology, KIST School, University of Science and Technology (UST), Seoul 02792, Republic of Korea.
- AmtixBio Co., Ltd., Hanam-si, Gyeonggi-do 12925, Republic of Korea.
- College of Pharmacy, Gachon University, Hambangmoe-ro 191, Yeonsu-gu, Incheon 21936, Republic of Korea.
ORCID-Profile: Bo Ko Jang, Ji Won Choi, Ki Duk Park
Förderung
- Korea Drug Development Fund
- National Research Foundation of Korea
Zitieren
APA
Seo, K. H., Jang, B. K., Yeon, S. K., Kim, H. J., Lee, Y. R., Seo, R., Lee, W. J., Kim, Y., Lee, E. H., Lee, D. G., Lee, H. S., Park, J. H., Shim, W. S., Lee, J. S., Choi, J. W., & Park, K. D. (2026). Synthetic Strategy and Evaluation of the Benzyloxy Benzylamide Derivatives as Thymic Stromal Lymphopoietin Modulators for the Treatment of Atopic Dermatitis. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02461
Vancouver
Seo KH, Jang BK, Yeon SK, Kim HJ, Lee YR, Seo R, et al. Synthetic Strategy and Evaluation of the Benzyloxy Benzylamide Derivatives as Thymic Stromal Lymphopoietin Modulators for the Treatment of Atopic Dermatitis. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c02461
BibTeX
@article{Seo2026,
author = {Seo, Kyoung Hee and Jang, Bo Ko and Yeon, Seul Ki and Kim, Hyeon Ji and Lee, Ye Rim and Seo, Ran and Lee, Wok-Joo and Kim, Yoowon and Lee, Elijah Hwejin and Lee, Dong-Gi and Lee, Han-Seung and Park, Jong-Hyun and Shim, Won-Sik and Lee, Jong-Seung and Choi, Ji Won and Park, Ki Duk},
title = {Synthetic Strategy and Evaluation of the Benzyloxy Benzylamide Derivatives as Thymic Stromal Lymphopoietin Modulators for the Treatment of Atopic Dermatitis},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.5c02461}
}
EUVIMED